Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling vs Conventional Therapy in Refractory Cancer (SHIVA)
NCT01771458Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Oct 2012
- Primary completion
- Oct 2016
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib, everolimus, vemurafenib, sorafenib, erlotinib in Not applicable, metastatic solid tumor, sponsored by Institut Curie. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
Not applicablemetastatic solid tumor
Beyond the preview
Go deeper on NCT01771458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01771458.